ALLR:NASDAQ, Allarity Therapeutics, Inc.
ALLR stock overview
Allarity Therapeutics, Inc. (ALLR:NASDAQ) closed at $0.785 on November 20, 2026,
down 9.25% on the day.
The stock trades 57.3% below its 52-week high of $1.84
and 2.1% above its 52-week low of $0.769.
Over the past year, it lost 32.9%.
Allarity Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $0.785
- Day change
- -9.25%
- Volume
- 305,151
- Average volume
- 128,714
- Market cap
- 12M+
- 52-week range
- $0.769 – $1.84
- 50-day average
- $0.979
- 200-day average
- $1.21
Price action over the past year
In 252 trading sessions since November 20, 2025, ALLR closed higher on 111 days (44%).
Its best day was March 6, 2026 (+21.57%) and its worst was October 12, 2026 (-13.13%).
The stock moved 10% or more in a single session 14 times.
Recent signals
ALLR news
-
Nov 18, 2026:
Allarity Therapeutics Granted U.S. Patent for Stenoparib's Clinical Dosing Regimen, with Protection Into 2045
-
Nov 16, 2026:
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
-
Nov 13, 2026:
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
-
Oct 30, 2026:
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
-
Oct 9, 2026:
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
-
Oct 5, 2026:
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
-
Sep 30, 2026:
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor to Drive Stenoparib's Clinical Development
-
Sep 30, 2026:
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development
About Allarity Therapeutics, Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra.
Similar stocks
Find more stocks like ALLR with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.